Ben Tre Pharmaceutical JSC (STC:DBT) 3-Year EBITDA Growth Rate: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STC:DBT Ben Tre Pharmaceutical JSC STC:DBT
14 GF Score
Price ₫13,700.00
! 1 Warning Sign
View Full Analysis

What is Ben Tre Pharmaceutical JSC 3-Year EBITDA Growth Rate?

Ben Tre Pharmaceutical JSC STC:DBT 14 3-Year EBITDA Growth Rate is 0.00% as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 812 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 123152.59% on this metric.

Ben Tre Pharmaceutical JSC's EBITDA per Share for the six months ended in . 20 was ₫0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Ben Tre Pharmaceutical JSC  (STC:DBT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Ben Tre Pharmaceutical JSC 3-Year EBITDA Growth Rate Related Terms

STC:DBT vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ben Tre Pharmaceutical JSC 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Ben Tre Pharmaceutical JSC's 3-Year EBITDA Growth Rate falls into.


STC:DBT
14GF Score
Ben Tre Pharmaceutical JSC STC:DBT
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ben Tre Pharmaceutical JSC 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Ben Tre Pharmaceutical JSC (STC:DBT) has a 3-Year EBITDA Growth Rate of 0.00% as of . 20. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 812 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's 3-Year EBITDA Growth Rate too high?
Ben Tre Pharmaceutical JSC's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 812 companies for 3-Year EBITDA Growth Rate. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.75, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Ben Tre Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Ben Tre Pharmaceutical JSC's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current 3-Year EBITDA Growth Rate is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ben Tre Pharmaceutical JSC Business Description

Address No. 6A3, National Highway 60, Phu Tan Ward, Vinh Long Province, Ben Tre, VNM
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
14GF Score

Get the complete analysis for STC:DBT

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫13,700.00
Price